NO2667877T3 - - Google Patents

Info

Publication number
NO2667877T3
NO2667877T3 NO12702934A NO12702934A NO2667877T3 NO 2667877 T3 NO2667877 T3 NO 2667877T3 NO 12702934 A NO12702934 A NO 12702934A NO 12702934 A NO12702934 A NO 12702934A NO 2667877 T3 NO2667877 T3 NO 2667877T3
Authority
NO
Norway
Application number
NO12702934A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2667877(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2667877T3 publication Critical patent/NO2667877T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Anesthesiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO12702934A 2011-01-26 2012-01-25 NO2667877T3 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161436274P 2011-01-26 2011-01-26

Publications (1)

Publication Number Publication Date
NO2667877T3 true NO2667877T3 (fr) 2018-08-04

Family

ID=45567134

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12702934A NO2667877T3 (fr) 2011-01-26 2012-01-25

Country Status (26)

Country Link
US (8) US9119772B2 (fr)
EP (2) EP2667877B1 (fr)
JP (1) JP6008876B2 (fr)
KR (1) KR101914940B1 (fr)
CN (2) CN103415292A (fr)
AR (1) AR084932A1 (fr)
AU (4) AU2012209184B2 (fr)
BR (1) BR112013019257B1 (fr)
CA (1) CA2825396C (fr)
CL (1) CL2013002134A1 (fr)
DK (1) DK2667877T3 (fr)
ES (1) ES2672238T3 (fr)
HU (1) HUE037660T2 (fr)
IL (1) IL227573A (fr)
MX (1) MX344046B (fr)
MY (1) MY175318A (fr)
NO (1) NO2667877T3 (fr)
PH (1) PH12013501579A1 (fr)
PL (1) PL2667877T3 (fr)
RU (1) RU2599036C2 (fr)
SG (1) SG192114A1 (fr)
TR (1) TR201807857T4 (fr)
TW (1) TWI593412B (fr)
UA (1) UA114705C2 (fr)
WO (1) WO2012103186A2 (fr)
ZA (1) ZA201305812B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
AU2012209184B2 (en) 2011-01-26 2017-06-15 Allergan, Inc. Androgen composition for treating an opthalmic condition
WO2013181339A2 (fr) 2012-06-01 2013-12-05 Allergan, Inc. Analogues de cyclosporine a
EP2968365A1 (fr) 2013-03-15 2016-01-20 Malhotra, Raman Administration systémique d'androgène dans le traitement du syndrome de l'oeil sec
RU2592370C9 (ru) * 2014-04-24 2016-08-27 Иван Иванович Дедов Средство на основе дегидроэпиандростерона, способ его применения
TWI516281B (zh) * 2014-07-16 2016-01-11 健維生技有限公司 改良之睪固酮製劑製法及所得之睪固酮製劑
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
TW201639873A (zh) 2015-01-08 2016-11-16 歐樂根公司 Ｍｅｂｍｔ側鏈已環化之環孢菌素衍生物
CN122075735A (zh) 2015-09-17 2026-05-26 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
WO2017055924A2 (fr) 2015-09-28 2017-04-06 M.G. Therapeutics Ltd. Agents contenant un thiol et un disulfure permettant d'augmenter la sécrétion lipidique des glandes de meibomius
EP3362096B1 (fr) 2015-10-14 2023-12-13 Paul Gavaris Composition de traitement ophtalmique et véhicule pour l'administration de substances pharmaceutiques ou d'agents thérapeutiques
WO2017178892A2 (fr) 2016-04-14 2017-10-19 M.G. Therapeutics Ltd. Compositions de disulfure de sélénium destinées à être utilisées dans le traitement du dysfonctionnement de la glande de meibomius
SG11201908454TA (en) * 2017-02-17 2019-10-30 Cempra Pharmaceuticals Inc Triazole-containing macrolides and ophthalmic uses therefor
JP6946575B2 (ja) * 2018-04-24 2021-10-06 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 眼の状態の治療のためのピロカルピン塩酸塩の使用
WO2020069450A1 (fr) * 2018-09-28 2020-04-02 Joel Studin Administration à travers les pores de médicaments et utilisations associées
US10744153B1 (en) 2019-07-01 2020-08-18 Cloudbreak Therapeutics Llc Compositions and methods for treating meibomian gland dysfunction
EP4087655A4 (fr) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd Instructions pour composition et sensibilité
US12440529B2 (en) 2020-09-22 2025-10-14 Alphyn Biologics, Inc. Topical Croton lechleri compositions and their use in the treatment of a bacterial colonization or primary or secondary bacterial infection of an underlying skin disorder
AU2022226676A1 (en) * 2021-02-25 2023-09-28 Alphyn Biologics, Llc Composition for treatment of topical dermatological bacterial skin conditions
US11746253B2 (en) * 2021-03-08 2023-09-05 Hoi Ming Michael HO Sprayable conductive agent capable of forming conductive portion and manufacturing method and use thereof
US11951123B2 (en) * 2022-01-12 2024-04-09 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease
CN115105512A (zh) * 2022-08-29 2022-09-27 中山大学中山眼科中心 脱氢表雄酮在制备预防、治疗眼部近视的药物中的用途及其剂型和制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262182A (en) * 1939-05-23 1941-11-11 John V Huskamp Closure valve for containers
US3049003A (en) 1956-09-05 1962-08-14 Clark Equipment Co Torque measurement apparatus
DE3514724A1 (de) * 1985-04-24 1986-10-30 Albin F. Dr. 4200 Oberhausen Jereb Salbe zur verbeugung und behandlung von augen- und hauterkrankungen
US5364632A (en) 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US6093706A (en) * 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
JPH07508716A (ja) 1992-04-21 1995-09-28 ザ　スキーペンズ　アイ　リサーチ　インスティテュート，インコーポレイテッド シェーグレン症候群における眼のアンドロゲン療法
US5688765A (en) * 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US5958912A (en) * 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
CA2157934A1 (fr) * 1993-03-12 1994-09-15 Timothy R. Willis Produits pour les yeux renfermant un additif de type pheronome; methode d'utilisation
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP0878197B1 (fr) 1997-05-14 2002-08-21 Senju Pharmaceutical Co., Ltd. Compositions à base de difluprednate
SI0999826T1 (en) * 1997-07-29 2004-12-31 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
US5981607A (en) * 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
JP2002541111A (ja) * 1999-04-01 2002-12-03 アクゾ・ノベル・エヌ・ベー ウンデカン酸テストステロンとヒマシ油を含む調合物
BR0015436A (pt) * 1999-11-09 2002-07-16 Alcon Inc Sais de hidroxieicosatetraenoato, composições e métodos de uso no tratamento de distúrbios dos olhos secos
US20020009507A1 (en) * 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
US20040214797A1 (en) * 2001-05-07 2004-10-28 Allergan, Inc. Preserved pharmaceutical compositions comprising cyclodextrins
US6872705B2 (en) * 2001-07-13 2005-03-29 Allergan, Inc. Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
WO2003030894A1 (fr) * 2001-10-11 2003-04-17 Alcon, Inc. Methodes de traitement des yeux secs
US6659985B2 (en) * 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US6983600B1 (en) * 2004-06-30 2006-01-10 General Electric Company Multi-venturi tube fuel injector for gas turbine combustors
EP1655021B1 (fr) 2004-11-09 2008-10-29 Novagali Pharma SA Emulsion huile-dans-eau à basse concentration de l'agent cationique et au potentiel de zéta positif
EP1858522A4 (fr) * 2005-03-02 2008-07-16 Pharmaceutical Inc Nascent Vecteur de qualité pharmaceutique pour préparations ophtalmiques
WO2006117910A1 (fr) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Anticorps monoclonal contre la glycoproteine vi de la membrane de la plaquette
US8697152B2 (en) * 2005-08-31 2014-04-15 Johnson & Johnson Consumer Companies, Inc. Anti-inflammatory compositions and personal care compositions comprising olive leaf (Olea europea) extract
SI2952197T1 (sl) 2005-10-26 2017-09-29 Cydex Pharmaceuticals, Inc. Sestavki sulfoalkil eter ciklodekstrina in metode priprave le-tega
US20070287983A1 (en) * 2006-06-07 2007-12-13 Richard Worthington Lodge Absorbent article having an anchored core assembly
US7390302B2 (en) 2006-08-16 2008-06-24 The General Electric Company Method and system of determining NIBP target inflation pressure using an SpO2 plethysmograph signal
US20080045486A1 (en) * 2006-08-17 2008-02-21 Tang-Liu Diane D S Ocular administration of testosterone
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US20100305046A1 (en) * 2009-06-02 2010-12-02 Abbott Medical Optics Inc. Stable cyclosporine containing ophthalmic emulsion for treating dry eyes
AU2012209184B2 (en) 2011-01-26 2017-06-15 Allergan, Inc. Androgen composition for treating an opthalmic condition

Also Published As

Publication number Publication date
US20170189412A1 (en) 2017-07-06
AU2019202511A1 (en) 2019-05-02
KR20140045327A (ko) 2014-04-16
US20180221388A1 (en) 2018-08-09
UA114705C2 (uk) 2017-07-25
AU2020267198A1 (en) 2020-12-10
CA2825396A1 (fr) 2012-08-02
EP2667877A2 (fr) 2013-12-04
AU2017228623A1 (en) 2017-10-05
BR112013019257A2 (pt) 2016-10-11
AR084932A1 (es) 2013-07-10
BR112013019257B1 (pt) 2019-09-03
MY175318A (en) 2020-06-19
JP6008876B2 (ja) 2016-10-19
DK2667877T3 (en) 2018-06-14
WO2012103186A2 (fr) 2012-08-02
CA2825396C (fr) 2016-09-06
ZA201305812B (en) 2014-04-30
PL2667877T3 (pl) 2018-09-28
EP3388066B1 (fr) 2020-11-04
TWI593412B (zh) 2017-08-01
PH12013501579A1 (en) 2022-10-26
IL227573A (en) 2017-04-30
US20140315872A1 (en) 2014-10-23
HUE037660T2 (hu) 2018-09-28
US20210268002A1 (en) 2021-09-02
MX344046B (es) 2016-12-02
US9119772B2 (en) 2015-09-01
MX2013008528A (es) 2013-08-29
AU2012209184B2 (en) 2017-06-15
EP2667877B1 (fr) 2018-03-07
RU2013138256A (ru) 2015-03-10
KR101914940B1 (ko) 2018-11-06
CN103415292A (zh) 2013-11-27
WO2012103186A3 (fr) 2012-09-20
TR201807857T4 (tr) 2018-06-21
US20150366800A1 (en) 2015-12-24
NZ613699A (en) 2015-09-25
US9504646B2 (en) 2016-11-29
JP2014503588A (ja) 2014-02-13
ES2672238T3 (es) 2018-06-13
TW201309302A (zh) 2013-03-01
US20120190661A1 (en) 2012-07-26
CL2013002134A1 (es) 2013-11-29
US20220202829A1 (en) 2022-06-30
US20210113588A1 (en) 2021-04-22
US9937188B2 (en) 2018-04-10
RU2599036C2 (ru) 2016-10-10
IL227573A0 (en) 2013-09-30
US10780098B2 (en) 2020-09-22
CN109700763A (zh) 2019-05-03
SG192114A1 (en) 2013-08-30
US10905696B2 (en) 2021-02-02
EP3388066A1 (fr) 2018-10-17

Similar Documents

Publication Publication Date Title
BR112013022641A2 (fr)
BR112013031251A2 (fr)
BR112013027245A2 (fr)
BR112013024383A2 (fr)
BR112013026905A2 (fr)
BR112013022995A2 (fr)
BR112013017670A2 (fr)
BR112013027830A2 (fr)
AP3853A (fr)
BR112013023927A2 (fr)
BR112013024365A2 (fr)
BR112013028733A2 (fr)
BR112013027121A2 (fr)
BR112013026790A2 (fr)
BR112013024588A2 (fr)
BR112013031556A2 (fr)
BR112013032368A2 (fr)
BR112013018949A2 (fr)
BR112013032377A2 (fr)
BR112013027836A2 (fr)
BR112013027761A2 (fr)
BR112013021637A2 (fr)
BR112013025487A2 (fr)
BR112013023266A2 (fr)
BR112013030734A2 (fr)